Johnson Bryon D, Taylor Patricia A, Stankowski Marja C, Talib Sohel, Hearst John E, Blazar Bruce R
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
Biol Blood Marrow Transplant. 2002;8(11):581-7. doi: 10.1053/bbmt.2002.v8.abbmt080581.
Donor T-cells can provide a graft-versus-leukemia effect and help to promote donor engraftment after allogeneic BMT; however, these benefits can be outweighed by the ability of the cells to induce life-threatening GVHD. Photochemical treatment (PCT) of T-cells with S-59 psoralen and long-wavelength UV-A light can inhibit their proliferative capacity and significantly decrease their ability to induce acute GVHD after allogeneic BMT. PCT donor T-cells have been shown to facilitate donor engraftment in a myeloablative BMT model. In this study, we examined whether donor T-cells subjected to PCT ex vivo could retain the ability to facilitate engraftment or increase donor chimerism after nonmyeloablative BMT or after establishment of mixed hematopoietic chimerism. In a transplantation model in which mice were conditioned for BMT with sublethal (600 cGy) TBI, an infusion of PCT donor T-cells was unable to facilitate engraftment of donor BM. A BMT model was used in which a mixture of allogeneic and syngeneic marrow cells was infused into lethally irradiated recipients for establishment of mixed hematopoietic chimerism. The goal was to determine whether PCT donor splenocytes could increase levels of donor chimerism. Recipients of splenocytes treated with UV-A light only (no S-59 psoralen) and given at the time of BMT or in a donor lymphocyte infusion (DLI) had significantly higher levels of donor chimerism than did recipients of BM only. Although PCT donor splenocytes given at the time of BMT modestly increased donor chimerism, PCT donor splenocytes given in a DLI did not increase donor chimerism. A nonmyeloablative BMT model was employed for determining whether DLI given relatively late after BMT could increase donor chimerism. Recipient mice were conditioned for BMT with a combination of low-dose TBI (50 or 100 cGy) and anti-CD154 (anti-CD40L) monoclonal antibody for achievement of low levels of mixed chimerism. When control mixed chimeras were given a DLI 71 days after BMT, donor chimerism was significantly increased. In contrast, PCT of the donor cells eliminated the ability of the cells to increase donor chimerism after infusion. Together results from these 3 distinct BMT models indicate that PCT of donor T-cells significantly inhibited the ability of the cells to facilitate donor engraftment after nonmyeloablative BMT or to increase donor chimerism in mixed hematopoietic chimeras when the cells were administered in a DLI.
供体T细胞可产生移植物抗白血病效应,并有助于促进异基因骨髓移植后供体的植入;然而,这些益处可能会被这些细胞诱导危及生命的移植物抗宿主病(GVHD)的能力所抵消。用S-59补骨脂素和长波长紫外线A光对T细胞进行光化学处理(PCT),可抑制其增殖能力,并显著降低其在异基因骨髓移植后诱导急性GVHD的能力。已证明PCT供体T细胞在清髓性骨髓移植模型中有助于供体植入。在本研究中,我们检测了经体外PCT处理的供体T细胞在非清髓性骨髓移植后或混合造血嵌合体形成后,是否仍保留促进植入或增加供体嵌合率的能力。在一个移植模型中,用亚致死剂量(600 cGy)的全身照射(TBI)对小鼠进行骨髓移植预处理,输注PCT供体T细胞并不能促进供体骨髓的植入。使用了一个骨髓移植模型,将同种异体和同基因骨髓细胞的混合物输注到接受致死性照射的受体中,以建立混合造血嵌合体。目的是确定PCT供体脾细胞是否能提高供体嵌合率。仅接受紫外线A光(无S-59补骨脂素)处理并在骨髓移植时或供体淋巴细胞输注(DLI)时给予的脾细胞受体,其供体嵌合率显著高于仅接受骨髓移植的受体。虽然在骨髓移植时给予PCT供体脾细胞可适度提高供体嵌合率,但在DLI时给予PCT供体脾细胞并不能提高供体嵌合率。采用非清髓性骨髓移植模型来确定骨髓移植后较晚给予DLI是否能提高供体嵌合率。用低剂量TBI(5~100 cGy)和抗CD154(抗CD40L)单克隆抗体联合对受体小鼠进行骨髓移植预处理,以实现低水平的混合嵌合体。当对照混合嵌合体在骨髓移植后71天接受DLI时,供体嵌合率显著增加。相比之下,供体细胞的PCT消除了细胞在输注后提高供体嵌合率的能力。这3个不同骨髓移植模型的结果共同表明,供体T细胞的PCT显著抑制了细胞在非清髓性骨髓移植后促进供体植入或在DLI时给予细胞后提高混合造血嵌合体中供体嵌合率的能力。